<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01501669</url>
  </required_header>
  <id_info>
    <org_study_id>NCCCTS-11-536</org_study_id>
    <nct_id>NCT01501669</nct_id>
  </id_info>
  <brief_title>Irinotecan/Capecitabine Versus Capecitabine in Patients Treated With A/T for HER2 Negative Metastatic Breast Cancer</brief_title>
  <acronym>PROCEED</acronym>
  <official_title>Phase III Multicenter Randomized Open-label Study of Irinotecan Plus Capecitabine Versus Capecitabine in Patients Previously Treated With Anthracycline and Taxane for HER2 Negative Metastatic Breast Cancer[PROCEED]</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Center, Korea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chung-Ang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Inha University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Korea University Anam Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Center, Korea</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multicenter, randomized study, open-label, phase III study.The efficacy of&#xD;
      irinotecan and capecitabine combination will be superior to capecitabine alone in term of&#xD;
      progression free survival in metastatic breast cancer patients previously treated with&#xD;
      anthracycline and taxane.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prior to enrollment, patients will be confirmed for hormone and HER2 receptor status.&#xD;
      Patients may have either measurable and/or evaluable metastatic lesions which are able to be&#xD;
      assessed by chest, abdomen CT and bone scan performed within 28 days prior to start of&#xD;
      treatment.&#xD;
&#xD;
        -  Capecitabine alone arm: 1250 mg/m2, BID, day 1-14, every 3 weeks&#xD;
&#xD;
        -  Irinotecan plus capecitabine arm : Irinotecan 80 mg/m2, day 1 and 8, every 3 weeks +&#xD;
           capecitabine 1000 mg/m2, BID, day 1-14, every 3 weeks.&#xD;
&#xD;
      Randomization will be done using a random block size permutation method and stratified based&#xD;
      on : hormone receptor status (negative vs. positive), first line vs. more than second lines,&#xD;
      visceral metastasis (negative vs. positive).&#xD;
&#xD;
      Treatment will continue until disease progression, death, or discontinuation due to side&#xD;
      effects of drugs or refusal by patients.&#xD;
&#xD;
      The primary objective of this study is to estimate the PFS of capecitabine and irinotecan in&#xD;
      patients with anthracycline and taxane- pretreated metastatic breast cancer, which will be&#xD;
      estimated by the Kaplan-Meier method and compared by log-rank test. Overall survival will be&#xD;
      also estimated by same method. The secondary statistical analysis consisting of an estimation&#xD;
      of the complete and partial response rates and response rates of the treatment will be&#xD;
      calculated as the ratio of the number of complete and partial responders to the total number&#xD;
      of evaluable patients and toxicity profile, which will be estimated as the ratio of the&#xD;
      number of occurrence to the total number of evaluable patients. A 95% confidence interval for&#xD;
      the response rate is computed based on the binomial distribution function. The analysis for&#xD;
      reporting the final treatment results will be undertaken when each patient has been&#xD;
      potentially followed for a minimum of 12 months. The overall survival and progression free&#xD;
      survival, and their respective medians will be estimated with 95% confidence intervals.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2011</start_date>
  <completion_date type="Anticipated">February 2014</completion_date>
  <primary_completion_date type="Anticipated">February 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>The analysis for reporting the final treatment results will be undertaken when each patient has been potentially followed for a minimum of 12 months</time_frame>
    <description>Day between the date of enrollment to the date of disease progression or death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate Overall survival (OS) Toxicity Quality of life (QoL) Pharmacogenomic study of irinotecan and capecitabine</measure>
    <time_frame>The analysis for reporting the final treatment results will be undertaken when each patient has been potentially followed for a minimum of 12 months</time_frame>
    <description>Objective response rate Overall survival (OS) Toxicity Quality of life (QoL) Pharmacogenomic study of irinotecan and capecitabine</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">222</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Capecitabine alone arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>X arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Irinotecan plus capecitabine arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan, Capecitabine</intervention_name>
    <description>Irinotecan 80 mg/m2, day 1 and 8, every 3 weeks&#xD;
+ capecitabine 1000 mg/m2, BID, day 1-14, every 3 weeks</description>
    <arm_group_label>Irinotecan plus capecitabine arm</arm_group_label>
    <other_name>IX arm</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed stage IV or recurrent breast cancer&#xD;
&#xD;
          -  HER2 negative disease, or HER2 unknown disease not eligible for anti-HER2 therapy&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Age ≥ 20 years&#xD;
&#xD;
          -  Patients who received anthracycline based chemotherapy in the (neo)adjuvant or&#xD;
             metastatic setting and experienced disease progression on taxane based chemotherapy in&#xD;
             the metastatic setting, or patients who experienced disease recurrence within 1 year&#xD;
             after completion of (neo)adjuvant anthracycline and taxane based chemotherapy&#xD;
&#xD;
          -  In case of patients treated with capecitabine in an adjuvant setting, disease&#xD;
             recurrence should not be occurred within 1 year after completion of capecitabine&#xD;
             chemotherapy&#xD;
&#xD;
          -  Patients with brain metastasis can be enrolled when they don't need any treatment&#xD;
             regarding to brain metastasis&#xD;
&#xD;
          -  Previous any chemotherapy and radiotherapy should be completed at least 3 weeks before&#xD;
             randomization- Measurable or evaluable disease according to the Response Evaluation&#xD;
             Criteria in Solid Tumors (RECIST) version 1.1 [21]&#xD;
&#xD;
          -  Adequate hematopoietic function: absolute granulocyte count ≥ 1,500/mm3, platelet ≥&#xD;
             100,000/mm3, hemoglobin ≥ 10g/mm3&#xD;
&#xD;
          -  Adequate hepatic function: total bilirubin ≤ 1.5mg/dL, alkaline phosphatase(ALP) ≤ 2.5&#xD;
             x UNL, AST/ALT ≤ 2x UNL, or if liver function abnormalities due to underlying&#xD;
             malignancy exists, AST/ALT ≤ 2.5 x UNL, total bilirubin ≤ 3.0mg/dL, (ALP) ≤ 5 x UNL in&#xD;
             cases with bone metastasis; ALP ≤ 5 x UNL&#xD;
&#xD;
          -  Adequate renal function : serum creatinine ≤ 1.5mg/dL&#xD;
&#xD;
          -  Ability to understand and comply with protocol during study period&#xD;
&#xD;
          -  Patients should sign a written informed consent before study entry&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Patients who receive irinotecan or capecitabine for metastatic breast cancer treatment&#xD;
&#xD;
          -  Patients with HER2 positive breast cancer&#xD;
&#xD;
          -  Grade 2 or greater peripheral neuropathy&#xD;
&#xD;
          -  Patients with symptomatic brain metastasis&#xD;
&#xD;
          -  Prior unanticipated severe reaction to fluropyrimidine therapy or known sensitivity to&#xD;
             5-fluorouracil&#xD;
&#xD;
          -  Patients who have history of cancer other than in situ cervical cancer or&#xD;
             non-melanotic skin cancer&#xD;
&#xD;
          -  Patients with GI tract disease resulting in an inability to take oral medication,&#xD;
             malabsorption syndrome, a requirement for IV alimentation, prior surgical procedure&#xD;
             affecting absorption, uncontrolled GI disease (e.g. Crohn's disease, ulcerative&#xD;
             colitis)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jungsil Ro</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cencer Center, Korea</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jungsil Ro</last_name>
    <phone>+82-31-920-1610</phone>
    <email>jungsro@ncc.re.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Inhae Park</last_name>
    <phone>+82-31-920-1680</phone>
    <email>parkih@ncc.re.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Cancer Center</name>
      <address>
        <city>Goyang-si</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jungsil Ro</last_name>
      <phone>+82-31-920-1610</phone>
      <email>jungsro@ncc.re.kr</email>
    </contact>
    <investigator>
      <last_name>Jungsil Ro</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>December 27, 2011</study_first_submitted>
  <study_first_submitted_qc>December 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 29, 2011</study_first_posted>
  <last_update_submitted>July 17, 2012</last_update_submitted>
  <last_update_submitted_qc>July 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Cancer Center, Korea</investigator_affiliation>
    <investigator_full_name>Jungsil Ro</investigator_full_name>
    <investigator_title>Chief, Center for Clinical Trials, National Cancer Center, Korea</investigator_title>
  </responsible_party>
  <keyword>irinotecan</keyword>
  <keyword>capecitabine</keyword>
  <keyword>metastatic breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

